WuXi AppTec's CRDMO model integrates drug discovery, development, testing, and manufacturing within one platform. By connecting capabilities across the drug development lifecycle, WuXi AppTec helps customers improve efficiency and accelerate new medicines to patients globally.
WuXi AppTec's CRDMO model integrates drug discovery, development, testing, and manufacturing within one platform. By connecting capabilities across the drug development lifecycle, WuXi AppTec helps customers improve efficiency and accelerate new medicines to patients globally.
CRDMO: An Integrated Model to Accelerate Life-sciences Innovation
A CRDMO, or Contract Research, Development, and Manufacturing Organization, is an integrated biopharmaceutical partnership model that connects drug discovery, development, testing, and manufacturing within one coordinated framework. It brings together capabilities commonly associated with CRO, CDMO, and CMO services, including process development, analytical testing, Investigational New Drug (IND)-enabling services, formulation, and commercial manufacturing.
For patients waiting for new treatments, better coordination across these stages can help address one of drug development's persistent challenges: transforming promising science efficiently into tangible solutions.
For global innovators, the value of a CRDMO lies in continuity. Drug development is full of handoffs: from discovery to development, from development to manufacturing, from one site to another, and from one technical team to the next. Each transition can introduce delays, knowledge gaps, quality risks, or duplicated work.
An integrated CRDMO reduces these handoffs by keeping more work within one coordinated platform or a single site. This shortens timelines, improves technical alignment, and creates a clearer path from early development to clinical and commercial supply.
In today's drug development landscape, the CRDMO model is becoming more relevant as pipelines increasingly include sophisticated modalities that require innovative delivery technologies and combination approaches. These programs often require specialized expertise, new analytical assays, and early consideration of manufacturability. The CRDMO model is not simply an outsourcing solution. It is a partnership model built around continuity, technical depth, and execution.
WuXi AppTec supports partners across more than 30 countries through operations spanning Asia, Europe, and North America. By integrating capabilities across research, development, testing, and manufacturing, WuXi AppTec collaborates with global innovators to advance promising science toward patients, guided by its vision that “every drug can be made and every disease can be treated.”
How WuXi Chemistry, WuXi Biology, and WuXi Testing Support the CRDMO Model
WuXi Chemistry provides integrated CRDMO services spanning drug discovery, development, scale-up, and commercial manufacturing. Its capabilities support synthetic molecular modalities across different development stages and scales, including small molecules, oligonucleotides, peptides, and complex conjugates.
By connecting chemistry research with downstream development and manufacturing, WuXi Chemistry supports continuity as drug candidates advance from early discovery toward clinical and commercial stages.
WuXi Chemistry: From Drug Discovery to Commercial Manufacturing
Drawing upon the early-stage drug discovery foundation, the CRDMO model also gains early insights into industry development opportunities, allowing us to plan capacity construction in advance to meet the evolving needs from global innovators.
Our combined development and manufacturing (D+M) services further empower early-stage innovators with comprehensive infrastructure, expertise, and technology needed to advance their pipeline at scale. With rapidly expanding capacity – spanning manufacturing of API, small molecules, peptides, oligonucleotides, and more - we are always ready to deliver when the demand for large-scale production rises.
Built on this foundation, WuXi AppTec's CRDMO model acts as a catalyst for healthcare innovation, seamlessly managing every stage from drug discovery to delivery. From small molecules, to emerging modalities, we are able to support all those transformative medicines that hold the promise to improve lives. Across oncology, immunology, neurological disorders, rare diseases, and many others, our efficiency translates directly to patients - faster access, more affordable treatments, and greater hope.
We're proud to work alongside our global partners to achieve the shared vision to build a future where "every drug can be made and every disease can be treated."
WuXi Biology: From Target Discovery to PCC
WuXi Biology provides a comprehensive spectrum of biology services and solutions, supporting stand-alone and integrated drug discovery projects. Its capabilities span target discovery, hit finding, lead optimization, candidate selection, and beyond, backed by established technology platforms and disease pharmacology expertise.
Within the CRDMO model, biology insights inform chemistry and program decisions across discovery and development, linking early science to downstream progression.
WuXi Testing: Integrated Testing Across Discovery and Development
WuXi Testing provides integrated testing capabilities across the discovery and development lifecycle. Its services support the evaluation of drug candidates as they progress from early research through preclinical and clinical development.
Within the CRDMO framework, WuXi Testing connects testing activities with discovery and development programs, helping generate the data needed to support candidate progression and the development of innovative medicines.
CRDMO in Action: How Integration Supports Drug Development
Integrated CRDMO programs accelerate drug development by connecting discovery, drug metabolism and pharmacokinetics (DMPK); toxicology, analytical development; chemistry, manufacturing, and controls (CMC); formulation; and manufacturing within one coordinated framework.
The following case studies illustrate how the CRDMO model supports measurable outcomes across different therapeutic modalities.
Targeted Protein Degrader: From Development Challenges to IND-Enabling Materials in 12 Months
Targeted protein degraders selectively remove disease-causing proteins rather than simply inhibit them, offering a potential way to address historically difficult-to-drug targets. Their structural complexity, however, can create challenges across synthesis, formulation, analytical development, and manufacturing.
In one targeted protein degrader program, WuXi AppTec supported development across these areas, shortening the synthetic route from 24 steps to 16 and improving oral bioavailability by approximately 30-fold. The program delivered IND-enabling materials and clinical trial formulations within 12 months, about two months ahead of the original schedule.
Oligonucleotide-Lipid Conjugate: From PCC to IND Submission in Eight Months
Oligonucleotide-lipid conjugates combine the sequence-specific activity of oligonucleotide therapeutics with lipid components that can influence delivery and distribution. However, their combined molecular complexity can create challenges in synthesis, purification, analytical characterization, formulation, and scale-up.
In one small interfering RNA (siRNA)-lipid conjugate program, WuXi AppTec supported development from the preclinical candidate (PCC) stage toward IND submission by advancing lipid synthesis, oligonucleotide production, process development, analytics, formulation, and manufacturing in parallel. The optimized process achieved up to 95% homogeneous conversion, improved crude purity by approximately 20%, maintained final API endotoxin below 0.05 EU/mg, and completed the required CMC activities within eight months.
Complex Stapled Peptide: Phase 2 Clinical Trial Material Released in 11 Months
Stapled peptides are engineered to improve peptide stability and maintain biologically active conformations, making them a promising modality for targeting protein–protein interactions that can be difficult to address with conventional small molecules. Their structural complexity, however, can create significant challenges in API development, purification, analytical characterization, formulation, and manufacturing.
In one complex triple-stapled peptide program, WuXi AppTec advanced analytical method development in parallel with API production under Good Manufacturing Practice (GMP) requirements, while process optimization reduced residual ruthenium by approximately 75-fold from crude material to final API. Formulation development also produced a stable injectable solution at a concentration above 100 mg/mL, and the program progressed from project onboarding to Phase 2 clinical trial material release within 11 months.
Radionuclide Drug Conjugate: Improving Development Speed, Purity, and Yield
A cyclic peptide-based radionuclide drug conjugate (RDC) program required rapid peptide optimization alongside process and analytical development. WuXi TIDES, WuXi AppTec's peptide and oligionucleotide platform, delivered more than 200 peptide variants at greater than 95% purity within four months. Working with WuXi Testing, the program further optimized molecular properties and evaluated lead compounds through in vitro and in vivo studies, ultimately supporting the client's nomination of a preclinical candidate.
As the RDC program advanced, process optimization reduced both synthesis cycle time and material consumption by approximately 30%. Improvements in impurity control and purification increased crude purity to 99% and raised overall yield from 29% to 44%, demonstrating how coordinated discovery, analytical, and process development can support RDC development from candidate optimization toward scalable manufacturing.
IND-Enabling Development: Coordinating DMPK, Toxicology, and Formulation
For a rare-disease program with limited regulatory precedent, IND preparation required coordinated assessment across DMPK, formulation, and toxicology. Cross-functional teams established an evaluation strategy and completed the required evaluation framework together with the full set of Good Laboratory Practice (GLP)-compliant toxicology studies in fewer than three months.
The coordinated approach supported the program's planned IND submission while demonstrating how DMPK, safety assessment, formulation, and regulatory preparation can be connected within an integrated development model.
These programs show how CRDMO integration can address different development bottlenecks. Rather than applying the same solution to every molecule, the model connects the scientific and operational capabilities needed for each program as it progresses.
Frequently Asked Questions About the CRDMO Model
CRDMO stands for Contract Research, Development, and Manufacturing Organization. It is an integrated biopharmaceutical partnership model that combines drug discovery, development, and manufacturing within one coordinated platform. Compared with fragmented outsourcing across multiple vendors, a CRDMO can reduce handoffs, improve knowledge continuity, and support greater consistency across the drug development lifecycle.
The model is particularly relevant for increasingly complex therapeutic modalities, including small molecules, peptides, oligonucleotides, and conjugated therapeutics, where close coordination across scientific disciplines and development stages is critical.
CROs, CDMOs, CMOs, and CRDMOs are related biopharmaceutical outsourcing models with different scopes. CROs commonly support discovery, preclinical, and clinical research; CDMOs support development, scale-up, and manufacturing; and CMOs focus primarily on manufacturing and supply.
CRDMOs span a broader portion of the drug development lifecycle by combining research, development, and manufacturing capabilities. This allows scientific knowledge, development strategy, analytical requirements, and manufacturing considerations to remain connected as a program advances.
Model
Full Name
Typical Scope
CRO
Contract Research Organization
Supports outsourced research activities such as discovery biology, chemistry, preclinical research, and clinical-related studies.
CDMO
Contract Development and Manufacturing Organization
Supports process development, formulation, clinical supply, scale-up, and commercial manufacturing.
CMO
Contract Manufacturing Organization
Focuses mainly on manufacturing, packaging, and supply for clinical or commercial products.
CRDMO
Contract Research, Development, and Manufacturing Organization
Connects research, development, and manufacturing in a continuous end-to-end model.
Through its CRDMO platform, WuXi AppTec provides capabilities commonly associated with CRO, CDMO, and CMO services, including discovery biology, chemistry, DMPK, testing, preclinical and IND-enabling services, process development, formulation, clinical supply, and commercial manufacturing.
Drug development requires decisions across chemistry, biology, DMPK, toxicology, analytics, process development, formulation, and manufacturing. Earlier cross-functional collaboration allows data generated in one area to inform decisions in others, helping teams identify development risks, prepare for IND submission, and coordinate activities that can proceed in parallel.
WuXi AppTec's CRDMO platform brings together complementary capabilities from WuXi Chemistry, WuXi Biology, and WuXi Testing. WuXi Chemistry supports synthetic molecular modalities from discovery through commercial manufacturing; WuXi Biology provides biology services from target discovery through candidate selection; and WuXi Testing supports DMPK, bioanalysis, toxicology, and other testing needs across discovery and development.
An integrated CRDMO can help biotech companies by providing: • Access to specialized capabilities without building every function internally. • Greater continuity from drug discovery through IND-enabling development and IND submission. • Parallel development of multiple workstreams to help shorten timelines. • Connected DMPK, CMC, testing, formulation, and manufacturing capabilities within one coordinated framework. • Reduced vendor coordination and fewer handoffs across development stages.
Provides CRDMO services for new drug development from discovery to commercial, meeting any material requirement at any scale and covering all categories for all synthetic molecular modalities, including small molecules, oligonucleotides, peptides and complex conjugates
WuXi Biology
A full spectrum of biology services and solutions, that support stand-alone and integrated projects, from target discovery to candidate selection and into the clinic
WuXi Testing
An integrated testing platform across the full life cycle of discovery and development to help customers deliver innovative medicines to patients.